Inactive Instrument

INSTEM

Equities

INS

GB00B3TQCK30

Instem : Notification of Major Holdings

April 19, 2021 at 04:31 am EDT

19 April 2021

Instem plc
('Instem' or 'the Company')

Holding(s) in Company

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that on 16 April 2021, DWT Holdings, Inc ('DWTH') notified the Company of its interest in 868,203 ordinary shares of ten pence each in the capital of the Company (the 'Ordinary Shares'), representing 3.99 per cent. of the Company's total voting rights.

As previously announced, the Ordinary Shares were issued to DWTH as part of the consideration for the acquisition of d-Wise Technologies, Inc ('d-Wise') which legally completed on 1 April 2021, with the Ordinary Shares being admitted to trading on AIM on 14 April 2021. DWTH will, in due course, transfer these Ordinary Shares to the two d-wise founding shareholders and 16 further employees.

Download the notification of major holdings (TR1):

TR-1: Standard form for notification of major holdings PDF

For further information, please contact:

Instem plc	Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser & Broker)	+44 (0) 20 7496 3000
Peter Steel / Alex Bond
Rachel Hayes
Wallbrook Financial PR	Tel: +44 (0) 20 7933 8780
Nick Rome	instem@walbrookpr.com
Tom Cooper
Nicholas Johnson

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

Instem solutions are in use by over 600 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

To learn more about Instem solutions and its mission, please visit instem.com.

Attachments

Original document
Permalink

Disclaimer

Instem plc published this content on 19 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 April 2021 08:30:01 UTC.

Latest news about INSTEM

Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline	Jan. 25	CI
Instem Delists from London Bourse's AIM After Merger with ArchiMed	Nov. 21	MT
France's Archimed Completes Acquisition of UK's Instem	Nov. 20	MT
Instem plc Announces Board Resignations	Nov. 20	CI
ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.	Nov. 19	CI
Instem acquisition by Ichor sanctioned by UK court	Nov. 16	AN
UK Court Clears Archimed’s Takeover of Instem	Nov. 16	MT
Actual Experience appoints administrators	Nov. 07	AN
Instem's Acquisition by Archimed's Ichor Management Granted UK Regulatory Nod	Nov. 07	MT
Instem shareholders back motions relating to Archimed offer	Nov. 03	AN
Instem, Archimed’s Ichor Management Agree Acquisition Deal Price	23-10-30	MT
Instem Postpones Court, General Meetings for Archimed Bid as New Suitors Surface	23-10-20	MT
Instem adjourns meeting after disclosing further approaches	23-10-18	AN
Instem shares fall back as Archimed says offer is final	23-10-13	AN
AIM WINNERS & LOSERS: TomCo raises funds; Instem bid "final"	23-10-13	AN
Archimed's Ichor Management Says GBP203 Million Cash Offer for Instem is Final	23-10-13	MT
Instem's second-largest shareholder opposes deal with PE firm Archimed	23-09-28	RE
Instem swings to loss in first half but posts revenue growth	23-09-15	AN
Instem plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-15	CI
Fears for the Chinese economy weigh on the FTSE 100	23-08-31
FTSE 100 Ends Higher, Helped by Hopes of US Rate Pause	23-08-30	DJ
UK Net Mortgage Approvals Fall As Interest Rates Remain High	23-08-30	DJ
FTSE 100 outperforms European peers	23-08-30	AN
AIM WINNERS & LOSERS: Instem soars on GBP200 million takeover	23-08-30	AN
Prudential outperforms; Instem jumps on takeover	23-08-30	AN

Chart INSTEM

Duration

Period

More charts

Company Profile

Instem plc is a United Kingdom-based company that is a provider of information technology (IT) solutions to the global life sciences market. The Company operates through four segments: Study Management, Regulatory Solutions, In Silico Solutions and Clinical Trial Acceleration. Study Management Solutions offers software that enables organizations to collect, review, manage and report discovery and preclinical data. Regulatory Solutions provides software, outsourced services and consulting for managing, storing, sharing, submitting and maintaining information compliant with agency regulations. The Company's In Silico Solutions enable researchers to generate scientific insights through the identification, extraction and analysis of information. Clinical Trials Acceleration Solutions offers technology solutions and consulting services to facilitate data integration, statistics, analytics and insights for companies of any size or stage of clinical trial analysis.

Sector

More about the company